TNGX
Tango Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$27.54-3.57%
Price as of Jul 20, 2026
TNGX profitability
Tango Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 97.3%
- EBITDA margin
- -184.5%
- EBIT margin
- -206.2%
- Net margin
- -188.2%
- Free cash flow margin
- -250.1%
Returns
- Return on equity
- -27.4%
- Return on assets
- -24.6%
- Return on invested capital
- -27.7%
- Asset turnover
- 0.14x
Cash efficiency
- Cash from operations
- -$141.5M
- Cash per share
- $2.63
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.